Cargando…

High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors

There are currently no established second- and later-line therapies for postmenopausal women with hormone receptor-positive advanced or metastatic breast cancer. We examined the efficacy of high-dose toremifene (HD-TOR) for this patient group and whether aromatase inhibitor (AI) resistance influence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fushimi, Atsushi, Tabei, Isao, Fuke, Azusa, Okamoto, Tomoyoshi, Takeyama, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037483/ https://www.ncbi.nlm.nih.gov/pubmed/32099680 http://dx.doi.org/10.1155/2020/7156574

Ejemplares similares

Male breast metastasis of ureteral cancer: a case report
por: Ishikawa, Yoshitaka, et al.
Publicado: (2020)

Complete remission from peritoneal metastasis of late recurrent breast cancer by endocrine therapy: a case report
por: Fuke, Azusa, et al.
Publicado: (2020)

Determination of the Optimum Excitation Wavelength for the Parathyroid Gland Using a Near-Infrared Camera
por: Tabei, Isao, et al.
Publicado: (2021)

Breast hemangioma with difficulty in preoperative diagnosis: a case report
por: Funamizu, Naotake, et al.
Publicado: (2014)

High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
por: Mori, Ryutaro, et al.
Publicado: (2014)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Toremifene interacts with and destabilizes the Ebola virus glycoprotein
por: Zhao, Yuguang, et al.
Publicado: (2016)

Subareolar breast abscess in male patients: a report of two patients with a literature review
por: Kazama, Takashi, et al.
Publicado: (2017)

Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene
por: Balducci, Chiara, et al.
Publicado: (2005)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells
por: Mimoto, Rei, et al.
Publicado: (2019)

Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer
por: Song, Dandan, et al.
Publicado: (2021)

Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
por: Fujimura, Tetsuya, et al.
Publicado: (2015)

Circumvention of Daunorubicin Resistance by a New Tamoxifen Derivative, Toremifene, in Multidrug‐resistant Cell Line
por: Urasaki, Yoshimasa, et al.
Publicado: (1994)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Inhibitory Effects of Toremifene on N‐Methyl‐N‐nitrosourea and Estradiol‐17β‐induced Endometrial Carcinogenesis in Mice
por: Niwa, Kenji, et al.
Publicado: (2002)

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
por: Thanopoulou, Eirini, et al.
Publicado: (2014)

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
por: Zagouri, F, et al.
Publicado: (2013)

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2022)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Incidental discovery of follicular lymphoma by sentinel lymph node biopsy and skin-sparing mastectomy for Paget’s disease associated with invasive breast cancer
por: Fushimi, Atsushi, et al.
Publicado: (2019)

Osteogenic cocktail induces calcifications in human breast cancer cell line via placental alkaline phosphatase expression
por: Fushimi, Atsushi, et al.
Publicado: (2020)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor?Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
por: Suh, Koung Jin, et al.
Publicado: (2017)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
por: PyrhÃ¶nen, S., et al.
Publicado: (1997)

Features of Microcalcifications on Screening Mammography in Young Women
por: Fushimi, Atsushi, et al.
Publicado: (2018)

A Case of Bilateral Trigger Thumbs Secondary to Aromatase Inhibitor
por: Lee, Jang Hyun, et al.
Publicado: (2015)

Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?
por: Brandi, Maria Luisa
Publicado: (2021)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen
por: Wang, Hongyue, et al.
Publicado: (2021)

Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase Inhibitor
por: Mendley, Susan R., et al.
Publicado: (2015)

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
por: Arpino, Grazia, et al.
Publicado: (2023)

Effects of Toremifene, a Selective Estrogen Receptor Modulator, on Spontaneous and Stimulated GH Secretion, IGF-I, and IGF-Binding Proteins in Healthy Elderly Subjects
por: Roelfsema, Ferdinand, et al.
Publicado: (2017)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
por: Shioi, Yoshihiro, et al.
Publicado: (2014)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_moqbpj3cpraqkl2gvq9ki3n94f